Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

@inproceedings{Tamminga2011Adenovirus5VectoredPF,
  title={Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component},
  author={Cindy L. Tamminga and Martha Sedegah and David P Regis and Ilin Chuang and Judith E. Epstein and Michele D. Spring and Jose Mendoza-Silveiras and Shannon McGrath and Santina Maiolatesi and Sharina M Reyes and Victoria Steinbeiss and Charlotte Fedders and Kathryn Smith and Brent House and Harini D. Ganeshan and Jennylynn Lejano and Esteban N. Abot and Glenna J. Banania and Renato Sayo and Fouzia Farooq and Maria Jesus Maldonado Belmonte and Jittawadee R Murphy and Jack L Komisar and Jackie Williams and Meng Shi and Donald J. Brambilla and Nalini Manohar and Nancy O. Richie and Chloe L Wood and Keith Limbach and Noelle B. Patterson and Joseph T. Bruder and Denise L. Doolan and C. Richter King and Carter L. Diggs and Lorraine A. Soisson and Daniel J. Carucci and Gail Levine and Sheetij Dutta and Michael R Hollingdale and Christian F. Ockenhouse and Thomas L. Richie},
  booktitle={PloS one},
  year={2011}
}
BACKGROUND A protective malaria vaccine will likely need to elicit both cell-mediated and antibody responses. As adenovirus vaccine vectors induce both these responses in humans, a Phase 1/2a clinical trial was conducted to evaluate the efficacy of an adenovirus serotype 5-vectored malaria vaccine against sporozoite challenge. METHODOLOGY/PRINCIPAL FINDINGS NMRC-MV-Ad-PfC is an adenovirus vector encoding the Plasmodium falciparum 3D7 circumsporozoite protein (CSP). It is one component of a… CONTINUE READING
34 Citations
92 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 92 references

Similar Papers

Loading similar papers…